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Multiple sclerosis (MS) is a progressive demyelinating process considered as an autoimmune disease, although the causes of
this pathology have not been yet fully established. Similarly to other neurodegenerations, MS is characterized by a series of
biochemical changes aﬀecting to diﬀerent extent neuronal functions; great attention has been given to oxidative/nitrosative stress
and to alterations in mitochondrial functions. According to previous data, MS patients show signiﬁcant changes in the circulating
concentrations of diﬀerent metabolites, although it is still unclear whether uric acid undergoes to decrease, increase, or no change
underthispathological condition.Inthisstudy,wereporttheserummetabolicproﬁleintermsofpurines,pyrimidines,creatinine,
malondialdehyde, ascorbic acid, nitrite, and nitrate in a group of 170MS patients. The results show increase in circulating uric
acid and other oxypurines (hypoxanthine and xanthine), as well as in uridine and β-pseudouridine. The concomitant increase in
circulatingcreatinine,malondialdehyde,nitrite,andnitrate,anddecreaseinascorbicacid,demonstratesthatMSinducesalteration
in energy metabolism and in oxidants/antioxidants balance that can be monitored in serum of MS patients.
1.Introduction
Multiple sclerosis (MS) is a progressive, invalidating patho-
logical state, the exact etiology of which is still uncertain [1].
It is considered as an autoimmune disease although the rea-
sons for the autoimmune demyelinization are far to be clear
[2]. At the molecular level, MS is characterized by a series of
biochemical changes aﬀecting neuronal functions [3], some
ofwhichareincommonwithotherneurodegenerationssuch
as Alzheimer’s [4] and Parkinson’s diseases [5]. Particularly,
one of these common features is the neuronal imbalance
in oxidants/antioxidants, with reactive oxygen species (ROS)
and reactive nitrogen species (RNS) as the excess oxidants
[6, 7] and uric acid as the putative defective antioxidant
[8–11]. Recently, mitochondrial malfunctioning has been
indicated to play a central role in the overall derangement
of brain metabolism observed in MS [12]. The consequences
of mitochondrial perturbation are critical for the correct
functioning of the electron transport chain coupled to
oxidative phosphorylation and, hence, for the maintenance
of the cell energy homeostasis. Furthermore, the abundant
literature has linked mitochondrial dysfunction with ROS
overﬂow [13]. If the imbalance in energy production and
consumption is operative, that is, the amount of ATP
produced does not satisfy the cell energy demand, it is
unavoidable that the purine nucleotide degradation pathway
is activated. This provokes an increased generation of nucle-
osides (adenosine, guanosine, and inosine) and oxypurines
(hypoxanthine, xanthine, and uric acid), which can freely
cross the cell membrane being released in part in the
extracellular space. In the brain tissue, this phenomenon
contributes to the signiﬁcant increase of these compounds
in the cerebrospinal ﬂuid (CSF) observed under diﬀerent
pathological states [14, 15], including MS [16].
Permeable metabolites generated in excess by transient
or chronic dysfunction of brain metabolism are sooner or2 Multiple Sclerosis International
later found into the blood stream, potentially contributing
to a signiﬁcant raise over their respective circulating phys-
iological levels [17, 18]. Therefore, several low-molecular-
weight compounds can be good candidate as potential blood
biomarkers of neurodegeneration. According to the present
knowledge, it is conceivable that compounds deriving from
ROS and RNS overproduction and metabolites generated
by altered energy metabolism might be detected in excess
in blood samples from MS patients, possibly being valid
predictors of the disease evolution. This logical cause-eﬀect
link has been proven for several compounds related to
ROS and RNS overproduction, so that increase in circu-
lating nitric oxide (NO) products [19, 20] and increase
in lipid peroxidation products [21] have been found in
plasma/serum of MS patients. Surprisingly, this does not
seem to apply to products deriving from the imbalance of
energy metabolism since several studies indicated signiﬁcant
decrease in plasma/serum concentrations of uric acid (the
end product of purine nucleotide catabolism) in MS patients
[22–25]. The rather improbable explanation for this fact is
that brain uric acid, acting as a potent NO scavenger, is
oxidized in consequence of the increased NO generation.
The ﬁnal result would be a signiﬁcant decrease in uric acid
circulating levels. In contrast to these results, a number of
clinical studies have indicated either no change [26, 27]
or increase [28, 29] in plasma/serum uric acid of MS
patients, thereby rendering unclear whether this compound
is modiﬁed under this pathological condition. Recently, we
reported a concomitant increase in the plasma and CSF
concentrations not only of uric acid but also of other
oxypurines and nucleosides in a cohort of MS patients [16,
30].
To reinforce our previous results, we here report the
metabolic proﬁle in terms of purines, pyrimidines, cre-
atinine, malondialdehyde (MDA), ascorbic acid, nitrite,
and nitrate determined in a group of 170 MS patients.
Concentrations of the various metabolites were compared
with those recorded in a group of 163 healthy controls. In
order to have indications on the potential clinical utility of
the routine metabolic proﬁling of MS patients, metabolite
changes were analyzed for a correlation with the severity of
the disease and MS subtypes.
2.MaterialsandMethods
2.1. Selection and Clinical Evaluation of the Patients. One
hundredandseventyMSpatientswereincludedinthisstudy.
They were assessed clinically at the Institute of Neurology of
the “Policlinico Gemelli” of the Catholic University of Rome,
using the Extended Disability Status Scale score (EDSS)
[31]. Patients were classiﬁed into relapsing remitting (RR),
secondary progressive (SP), or primary progressive (PP),
according to what described elsewhere [32]. The control
group consisted of 163 healthy subjects, matched for age
and gender, and recruited among the personnel of the
two Universities undergoing the annual health checkup. All
selected subjects had no acute or chronic pathologies. The
study was approved by the local Ethic Committee. Written
informed consents were obtained.
2.2. Preparation of Samples for the Serum Metabolic Proﬁling.
In both patients and controls, peripheral venous blood
samples were collected from the antecubital vein into VAC-
UETTE polypropylene tubes containing serum separator
and clot activator (Greiner-Bio One GmbH, Kremsmunster,
Austria). After 40 minutes at room temperature, samples
were centrifuged at 1890×g for 10min to separate sera.
Aliquots were ﬁrst diluted with doubly-distilled water (1:2,
v:v) and then deproteinized by ultraﬁltration, according
to a procedure described in detail elsewhere [33]. The
deproteinized ultraﬁltrate ﬂuid was used to quantify the
metabolites of interest using a single, ion-pairing, high-
performanceliquidchromatographic(HPLC)analysiswhich
allows the simultaneous isocratic separation of creatinine,
purines (hypoxantine, xanthine, uric acid, inosine, guano-
sine), pyrimidines (uracil, β-pseudouridine, thymine, uri-
dine, thymidine, orotic acid), ascorbic acid, MDA, nitrite,
and nitrate [33].
Deproteinized samples were loaded (200μL) onto a
Hypersil C-18, 250 × 4.6mm, 5μmp a r t i c l es i z ec o l u m n ,
provided with its own guard column (ThermoFisher Italia,
Rodano, Milan, Italy). The chromatographic column was
connected to an HPLC apparatus consisting of a SpectraSys-
tem P4000 pump system and a highly-sensitive UV6000LP
diode array detector (ThermoFisher Italia, Rodano, Milan,
Italy), equipped with a 5cm light path ﬂow cell and set up
between 200 and 300nm wavelength. Data acquisition and
analysis were performed by a PC using the ChromQuest
software package provided by the HPLC manufacturer.
Assignment and calculation of the compounds of interest in
chromatographic runs of biological ﬂuid extracts were car-
ried out at 206 (nitrite and nitrate), 234 (creatinine), or 260
(purines, pyrimidines, ascorbic acid, MDA) nm wavelengths
by comparing retention times, absorption spectra, and areas
of peaks with those of peaks of chromatographic runs of
freshly prepared ultrapure standard mixtures with known
concentrations.
2.3. Statistical Analysis. All variables were skewed and,
therefore, were log-transformed to approach Gaussian dis-
tribution before application of parametric tests. Diﬀerences
between controls and MS patients were assessed by the
Student’s t-test for unpaired observations. Due to the
diﬀerent number of subjects, diﬀerences among subgroups
of MS patients on EDSS or on clinical MS subtypes (RR, SP,
PP) were assessed by the Kruskal-Wallis one-way ANOVA by
ranks. A value of P<. 05 was considered signiﬁcant.
3. Results
The characteristics of both the MS patients and the control
group are summarized in Table 1. The clinical classiﬁcation
indicated that 66.5% of the patients were RR, 25.3% were SP,
and 8.2% only were PP.
3.1. Serum Metabolic Proﬁle of MS Patients: Purines, Pyrim-
idines,andCreatinine. Datareferringtothecirculatinglevels
of the diﬀerent metabolites under evaluation in controls andMultiple Sclerosis International 3
Table 1: Clinical features of MS patients and controls.
Controls MS patients
Number of patients 163 170
Female:male 106:57 115:55
Average age at onset NA 31.77 ± 11.72
Average age at assessment 43.45 ± 3.21 45.27 ± 6.80
Duration of pathology (years) NA 13.5 ± 5.22
RR NA 113
SP NA 43
PP NA 14
Average EDSS NA 3.26 ± 2.29
NA: not available.
RR: relapsing-remitting MS; SP: secondary progressive MS; PP: primary
progressive MS; EDSS: expanded disability scale score.
MS patients are reported in Table 2. With respect to values in
controls, the HPLC analysis of serum oxypurines evidenced
a2 . 9 4± 1.14-fold increase (mean ± standard deviation)
in the value of hypoxanthine (P<. 001), a 2.80 ± 1.53-
fold increase (mean ± standard deviation) in the value of
xanthine (P<. 001) and a 1.16 ± 0.27-fold increase (mean
± standard deviation) in the value of uric acid (P<. 001).
When considering the sum of circulating oxypurines in MS
patients (316.20 ± 72.21μmol/L serum; mean ± standard
deviation), a 1.21 ± 0.28-fold increase (mean ± standard
deviation) with respect to controls (261.16 ± 48.89μmol/L
serum; mean ± standard deviation; P<. 001) was observed.
These values are illustrated in the scatter plot of Figure 1(a);
in the same ﬁgure, levels of serum creatinine in controls
and MS patients are also reported (Figure 1(b)). Similarly to
what observed for oxypurines, value of circulating creatinine
in MS patients (71.10 ± 19.27μmol/L serum; mean ±
standard deviation) was 1.25 ± 0.34 times higher (mean ±
standard deviation) than that recorded in controls (56.87 ±
17.98μmol/L serum; mean ± standard deviation; P<. 001).
When MS patients were divided on the basis of the disability,
no one of the aforementioned metabolites correlated with
increasing EDSS. Diﬀerently, the classiﬁcation of the patients
into three subgroups on the basis of the MS subtypes
(Figure 2)showedthatRRpatientshadsigniﬁcantlydiﬀerent
values of creatinine, uric acid, and sum of oxypurines in
comparison to both SP (P<. 001) and PP patients (P<
.001).
Among the pyrimidine compounds, uracil, β-pseu-
douridine, and uridine were always detectable in all serum
samples analyzed using this HPLC method. Uracil concen-
tration in serum of controls (1.97 ± 0.90μmol/L serum;
mean ± standard deviation) did not diﬀer from that
measured in MS patients (2.11 ± 1.04μmol/L serum;
mean ± standard deviation). Viceversa, Figure 3 illustrates
that circulating uridine (a) and β-pseudouridine (b) were
signiﬁcantly diﬀerent in MS patients (7.20 ± 1.81 and 4.67 ±
1.71μmol/L serum, resp.; means ± standard deviations) and
controls (4.83 ± 2.19 and 3.03 ± 1.23μmol/L serum, resp.;
means ± standard deviations). Uridine and β-pseudouridine
did not correlate with increasing EDSS, nor they showed
Table 2: Concentration of circulating creatinine, pyrimidine (β-
pseudouridine and uridine), oxypurines (hypoxanthine, xanthine
and uric acid) malondialdehyde (MDA), nitrite and nitrate (NO2 +
NO3), and ascorbic acid determined by HPLC in serum samples of
healthy controls and MS patients.
Controls (n = 163) MS patients (n = 170)
Creatinine 56.87 ± 17.98 71.10 ± 19.27a
Uracile 1.97 ± 0.90 2.11 ± 1.04
β-pseudouridine 3.03 ± 1.24 4.67 ± 1.71a
Uridine 4.83 ± 2.19 7.20 ± 1.82a
Hypoxanthine 4.19 ± 1.58 12.30 ± 4.84a
Xanthine 1.44 ± 0.96 4.03 ± 2.20a
Uric acid 258.08 ± 50.39 299.88 ± 70.17a
MDA 0.005 ± 0.004 0.84 ± 0.54a
NO2 +N O 3 69.06 ± 29.04 107.94 ± 43.87a
Ascorbic acid 57.52 ± 14.81 37.36 ± 10.95a
Values are means ± standard deviations and are expressed in μmol/L serum.
asigniﬁcantly diﬀerent from controls (P<. 001).
signiﬁcant diﬀerences in the subgroups of patients divided
on MS subtypes.
3.2. Serum Metabolic Proﬁle of MS Patients: Oxidants and
Antioxidants. Figure 4 reports concentrations of circulating
MDA (a), as an index of lipid peroxidation, and of nitrite
+ nitrate (b), generated from nitric oxide decomposition, in
controls and MS patients. MDA in serum of MS patients
(0.84 ± 0.53μmol/L serum; mean ± standard deviation)
showed a tremendous 210 ± 132-fold increase (mean ±
standard deviation) in comparison with the concentration
measured in serum of controls (0.004 ± 0.003μmol/L
serum; mean ± standard deviation). Serum nitrite + nitrate
in MS patients (mean ± standard deviation = 107.94 ±
43.87μmol/L serum) was 1.56 ± 0.63-fold higher (mean ±
standard deviation) than the circulating value of these two
nitrogen anions measured in controls (69.05 ± 29.04μmol/L
serum; mean ± standard deviation).
Data in Figure 5 show that the serum concentration of
ascorbic acid in MS patients (37.36 ± 10.95μmol/L serum;
mean ± standard deviation) was 1.54 ± 0.45 times lower
(mean ± standard deviation) than that recorded in controls
(57.52 ± 14.81μmol/L serum; mean ± standard deviation),
thereby indicating a decrease in this circulating antioxidant
as a consequence of the increased oxidative/nitrosative
stress occurring in MS. It is worth recalling that MDA,
nitrite + nitrate, and ascorbic acid did not correlate with
increasing EDSS, nor they showed signiﬁcant diﬀerences in
the subgroups of patients divided on MS subtypes.
4. Discussion
Data reported in the present study conﬁrm our previous
ﬁndings obtained in a smaller group of MS patients [16, 30]
and indicate alterations of circulating compounds related
to energy metabolism, oxidative/nitrosative stresses, and
antioxidant status occurring in multiple sclerosis.4 Multiple Sclerosis International
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Figure 1: Scatter plot showing the sum of oxypurines (uric acid + hypoxanthine + xanthine) (a) and creatinine (b) recorded in serum of
163 healthy controls and 170MS patients. Horizontal bars indicate the mean values calculated in the two groups.
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Figure 2: Bar graph showing the mean values of creatinine, uric
acid, and sum of oxypurines (uric acid + hypoxanthine + xanthine)
in the 170MS patients divided on the basis of the clinical MS
subtype. RR: relapsing remitting; SP: secondary progressive; PP:
primary progressive. Standard deviations are indicated by vertical
bars. Asterisk = signiﬁcantly diﬀerent from RR (P<. 01).
Most of the studies suggest that circulating concen-
trations of uric acid, which metabolically derives from
catabolism of phosphorylated purines (ATP and GTP) and
also from nucleic acid degradation, are decreased in MS
patients [22–25]. However, a meaningful body of the litera-
ture contrasts this evidence, indicating that MS patients have
levels of plasma/serum uric acid comparable or higher than
those recorded in controls [26–29]. In the present cohort
of 170MS patients, conﬁrming our previous observations
[16, 30], we again found higher concentrations in serum uric
acid than those recorded in 163 age- and gender-matched
healthy controls (Table 2). This increase in serum uric acid
was accompanied by an almost three times raise in both
hypoxanthine and xanthine, thus rendering more evident
the overall net increase in circulating oxypurines associated
with MS (Figure 1(a)). Furthermore, although none of the
aforementioned parameters correlated with EDSS, either
uric acid or the sum of oxypurines did correlate with the
MS clinical subtypes, with the RR subgroup showing lower
values than those found in both the SP and the PP subgroups
(Figure 2).
The three oxypurines considered are mainly produced
along the cascade of purine nucleotide degradation, when
energy metabolism does not satisfy the cell/tissue ATP
demand [34, 35]. Hence, it is conceivable to aﬃrm that
MS patients might suﬀer from imbalance between energy
production and consumption. Since the machinery to ensure
adequate ATP production is localized in mitochondria, the
recent data showing neuronal mitochondrial malfunctioning
in MS [12] corroborate the hypothesis that the increase
in circulating oxypurines in our patients is the direct
consequence of altered mitochondrial functions. Certainly,
our results do not support the notion sustained by var-
ious studies which aﬃrm that MS patients have lower
plasma/serum uric acid than controls [22–25]. In particular,
since MS patients suﬀer from increased oxidative/nitrosative
stress [6, 7], it has been suggested that decrease of circulating
uric acid in MS is due to the potent uric acid scavenging
activity towards peroxynitrite [9]. Together with the results
on the full proﬁle of serum purine compounds, our data
evidenced a decline in circulating antioxidant defenses of
MS patients, in terms of ascorbic acid and not of uric
acid decrease (Figure 5). Ascorbic acid, a hydrophilic low-
molecular-weight antioxidant, is not synthesized by the
human body and adequate amount should, therefore, be
assumed with the diet to allow a reasonable distribution
by the blood stream to the diﬀerent tissues. The brain has
a speciﬁc transporter for ascorbic acid devoted to permit
that this compound can cross the blood brain barrier and
is accumulated within the cerebral cells, against a concen-
tration gradient [36, 37]. Through this facilitated transport
mechanism, cerebral ascorbic acid reaches the concentration
of about 2300nmoL/g wet weight (corresponding to about
2500μmol/L brain water) and is the second most abundant,
water-soluble, brain antioxidant [38, 39]. Ascorbic acid has
the same aﬃnity for peroxynitrite than that of uric acid [9],
but in the brain it is about 1000 times more concentrated
than uric acid [16, 40]. Even if cerebral uric acid had a role asMultiple Sclerosis International 5
0
2
4
6
8
10
12
U
r
i
d
i
n
e
Controls MS patients
(
μ
m
o
l
/
s
e
r
u
m
)
L
(a)
0
2
4
6
8
10
β
-
p
s
e
u
d
o
u
r
i
d
i
n
e
Controls MS patients
(
μ
m
o
l
/
s
e
r
u
m
)
L
(b)
Figure 3: Scatter plot showing the concentrations of uridine (a) and β-pseudouridine (b) recorded in serum of 163 controls healthy and
170MS patients. Horizontal bars indicate the mean values calculated in the two groups.
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Figure 4: Scatter plot showing the concentrations of MDA (a) and sum of nitrite and nitrate (b) recorded in serum 163 controls healthy and
170MS patients. Horizontal bars indicate the mean values calculated in the two groups.
anantioxidant,itappearsevidentthatinthecaseofincreased
oxidative/nitrosative stress a decrease in brain ascorbic acid
rather than in uric acid would certainly occur. Cerebral uric
acid would be oxidized only when the concentration ratio
ascorbic acid/uric acid in the brain were in favor of uric
acid. According to the present results, our cohort of MS
patients, in consequence of increased oxidative/nitrosative
stress (Figure 4), showed a 35% decrease in circulating
ascorbic acid. Such a decrease might render less eﬃcient
the mechanism of its cerebral accumulation and to reduce,
in turn, the brain antioxidant capacity. If the decrease in
serum ascorbic acid was hypothetically mirrored by an equal
decrease in the brain tissue, cerebral ascorbic acid would
then be 1400–1500nmoL/g wet weight, that is, still 700 times
higherthanbrainuricacid[16,40].Therefore,itappearsthat
even in conditions of increased oxidative/nitrosative stress,
there are not the biochemical presuppositions to sustain a
role of uric acid as a valid brain tissue antioxidant, nor to
imagine that MS might provoke its decrease in serum.
The evidence of impaired energy metabolism in our MS
patients was also supported by data referring to circulating
uridine, the value of which was 1.5 times higher than
that found in controls (Figure 3(a)). According to previous
observations [41], the increase in plasma uridine can be
considered as an indirect indicator of tissue energy crisis.
In fact, in conditions of metabolic energy imbalance in
humans, it has clearly been demonstrated a close association
between myocardial ATP exhaustion and the increase either
in circulating purines (hypoxanthine, xanthine, uric acid),
or in circulating uridine [42]. This reinforces the concept
that changes in plasma uridine reﬂect changes in cell/tissue
energy metabolism. The overall conclusion, when analyzing
results of circulating purines and pyrimidines, is that MS
patients suﬀer indeed from energy deﬁcit, probably in6 Multiple Sclerosis International
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Figure 5: Scatter plot showing the concentration of ascorbic acid
recorded in serum 163 healthy controls and 170MS patients.
Horizontal bars indicate the mean values calculated in the two
groups.
consequence of altered mitochondrial functions [12, 43, 44].
Since MS patients are at risk of a number of intercurrent
systemic inﬂammatory or noninﬂammatory conditions [45,
46], it cannot be excluded a signiﬁcant extracerebral contri-
bution in the overall serum increase of these metabolites.
In addition, the muscular involvement in MS [47, 48],
possibly caused by a metabolic imbalance of myocytes and
also recently evidenced by an increased cost of walking in
patients with mild disability [49], might further contribute
to exacerbate alterations in the serum metabolic proﬁle of
thesepatients.DataindicatinghigherserumcreatinineinMS
patients than in controls (Figure 1(b)) strongly reinforce this
concept.
In our MS patients, a signiﬁcant increase in serum β-
pseudouridine was also observed. Since this modiﬁed pyrim-
idine is exclusively found in transfer and ribosomal RNAs, its
increase in body ﬂuids is generally considered as an index
of increased rate of RNAs turnover, due to increased rate of
protein synthesis [50]. Since in experimental autoimmune
encephalomyelitis (EAE) protein synthesis has been shown
to increase 4-fold over the basal level [51], it may be
hypothesized that this phenomenon is responsible for the
increase in serum β-pseudouridine in MS patients.
In this study, the most dramatic change associated
with MS occurred to serum MDA (Figure 4(a)). This
compound, originating from the irreversible decomposition
of peroxidized polyunsaturated fatty acids of membrane
phospholipids, is considered a reliable indicator of increased
oxidative stress [52, 53], if properly assayed. In MS patients,
the 210-fold increase of MDA over the value recorded in
controls is the clear evidence that reactive oxygen species-
mediated lipid peroxidation is operative under this patho-
logical condition. Since we also found a signiﬁcant increase
in nitrite + nitrate in serum of MS patients (Figure 4(b)),
we can conclude that these patients are exposed to the
concomitant oxidative/nitrosative stress, stating that the sum
of these two nitrogen anions is considered as an index of
NO generation [54, 55]. This implies an elevated risk of
producing the highly oxidizing radical peroxynitrite ONOO.
with serious consequences for the brain tissue integrity.
The main limitations of this study are that changes in
serum metabolites failed to correlate with EDSS, probably
because of a low number of subjects in several patient sub-
groups. Even the diﬀerences recorded for some metabolites
when patients were divided into the three clinical MS sub-
types failed to discriminate SP from PP, most likely because
of the limited number of PP patients. Recruitment of
additional MS patients is in progress.
5. Conclusions
In conclusion, our results on the serum metabolic proﬁle
in MS clearly indicate that these patients suﬀer from a
profound purine and pyrimidine dysmetabolism, potentially
due to altered mitochondrial functions. This causes the
increase in circulating uric acid, hypoxanthine, xanthine,
creatinine, β-pseudouridine, and uridine, with creatinine,
uric acid, and sum of oxypurines being in correlation with
the clinical MS subtypes. The clear evidence of concomitant
oxidative/nitrosative stress suggests that possible therapeutic
approaches aimed to improve cerebral mitochondrial func-
tions and neuronal energy state, as well as to increase the
brainantioxidantdefenses,mightamelioratethestatusofMS
patients.
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